Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib | Zendy

David Sanford | Zendy; Maria MacDonald | Zendy; Michael Nicolle | Zendy; Anargyros Xenocostas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib

Author(s) -

David Sanford,

Maria MacDonald,

Michael Nicolle,

Anargyros Xenocostas

Publication year - 2014

Publication title -

hematology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.239

H-Index - 12

ISSN - 2038-8330

DOI - 10.4081/hr.2014.5288

Subject(s) - nilotinib , medicine , myasthenia gravis , myeloid leukemia , adverse effect , tyrosine kinase , tyrosine kinase inhibitor , oncology , immunology , imatinib , cancer , receptor

We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research